1832 Asset Management
SUPN icon

1832 Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

1832 Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-825,900
Closed -$48.3M – 714
2018
Q2 		$48.3M Buy
+825,900
New +$42.8M 0.16% 121
2017
Q3 		– Sell
-30,400
Closed -$1.31M – 727
2017
Q2 		$1.31M Sell
30,400
-21,800
-42% -$776K 0.01% 410
2017
Q1 		$1.64M Buy
52,200
+13,200
+34% +$354K 0.01% 423
2016
Q4 		$985K Sell
39,000
-16,600
-30% -$371K ﹤0.01% 449
2016
Q3 		$1.38M Buy
+55,600
New +$1.26M 0.01% 428

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

1832 Asset Management's SUPN Position: Q3 2018 in Review

1832 Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 825,900 shares — an estimated $48.3M sold.

1832 Asset Management first reported a position in SUPN in Q3 2016 and held it in 5 quarters. The position peaked at $48.3M in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • 1832 Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • 1832 Asset Management sold 825,900 Supernus Pharmaceuticals shares in Q3 2018, an estimated $48.3M.
  • 1832 Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • 1832 Asset Management's Supernus Pharmaceuticals position peaked at $48.3M in Q2 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on 1832 Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.